
Sign up to save your podcasts
Or
Alcon makes a major acquisition to bolster is vitreoretinal surgery portfolio; the European Commission (EC) approves Eylea 8 mg for extended treatment intervals; and Eric Donnenfeld, MD, discusses the business of myopia management.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Alcon makes a major acquisition to bolster is vitreoretinal surgery portfolio; the European Commission (EC) approves Eylea 8 mg for extended treatment intervals; and Eric Donnenfeld, MD, discusses the business of myopia management.
Learn more about your ad choices. Visit megaphone.fm/adchoices